1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Nuclear Medicine/Radiopharmaceuticals Global market - Forecast to 2020

Nuclear Medicine/Radiopharmaceuticals Global market - Forecast to 2020

  • August 2014
  • -
  • IQ4I Research & Consultancy Pvt. Ltd
  • -
  • 283 pages

Nuclear medicine deals with the radioisotope applications in diagnosis and treatment of disease. Radiopharmaceuticals are drugs containing radionuclide’s. Administration of radiopharmaceuticals facilitated to image bone, organs and the disease process in body at early stage based on cellular function and physiology. Around 200 radioisotopes are used regularly by the physicians for diagnosis and treatment across the globe. The global nuclear medicine/radiopharmaceutical market is segmented into diagnostic (SPECT and PET) and therapeutic areas (Beta, Alpha emitter, and Brachytherapy). Tc-99m and F-18 are proved to be the most dominant isotopes in SPECT and PET markets respectively. In addition, Rb-82 and Tl-201 are expected to register high growth in diagnostic market. Whereas Y-90 and Lu-177 are witnessing high growths in beta therapy radioisotopes market. Paediatrics, cardiology, oncology, neurology and psychiatry are some of the prominent applications areas of nuclear medicine.

Increase in use of SPECT and PET scans, and awareness by physicians for treatment of coronary heart disease, Alzheimer’s disease, breast cancer and bone metastasis are some of the major drivers of nuclear medicine market. Moreover, the growing therapeutic areas such as lymphoma, prostate cancer, bone metastasis, and hepatocellular carcinoma also play a crucial role in the market growth. Whereas, the half-life of radiopharmaceuticals, high capital demand, lack of proper GMP (Good Manufacturing Practice), and inefficient effluent treatment are found to be the major factors hampering the nuclear medicine/radiopharmaceutical market growth. Increasing medical applications, rising demand in emerging economies and technological advancements in neurological applications are providing growth opportunities while, stringent regulatory guidelines and shutdown of nuclear reactors for radioisotope production are considered to be the major threats to the market growth.

The global nuclear medicine/radiopharmaceutical market is poised to reach around $6 billion by 2017 at a CAGR of more than 7%. The largest share in the global radiopharmaceuticals market is accounted by North America. Besides U.S. market Asia-Pacific region is also poised to show a remarkable growth. The Asia-Pacific radiopharmaceutical market is poised to reach approximately 14% by 2017 at a CAGR of around 11%. Countries such as China, India, Japan, South Korea, Brazil and South Africa possess reactors and other production units for isotopes. Moreover, the government initiative in funding the isotope manufacturers is also expected to boost the market growth.

The global nuclear medicine/radiopharmaceutical market is majorly comprised of five key players accounting for around 50% of the total market share. Key players include Covidien (), IBA Group, Lantheus Medical Imaging, Nordion, Triad Isotopes, Siemens Healthcare (PETNET Solutions), and NTP Radioisotopes. Acquisitions and mergers, new product launch, agreements and collaborations, and expansions were the main strategies followed by the key players in the global nuclear medicine market.

The report provides an in depth market analysis of the above mentioned segments across the following regions:
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)

Table Of Contents

Nuclear Medicine/Radiopharmaceuticals Global market - Forecast to 2020
1. Executive Summary.

2. Introduction.
2.1. Key Take Aways.
2.2. Report Description.
2.3. Markets Covered.
2.4. Stakeholders.
2.5. Research Methodology.
2.5.1. Market Size Estimation.
2.5.2. Market Breakdown and Data Triangulation.
2.5.3. Secondary Sources.
2.5.4. Primary Sources.
2.5.5. Key Data Points From Secondary Sources.
2.5.6. Key Data Points From Primary Sources.
2.5.7. Assumptions.

3. Market Analysis.
3.1. Introduction.
3.2. Market Segmentation.
3.3. Factors Influencing Market.
3.3.1. Drivers and Opportunities.
3.3.1.1. Increased Application Of Radio Pharmaceuticals.
3.3.1.2. Rise In Public Awareness.
3.3.1.3. Usage Of Hybrid Imaging.
3.3.1.4. Abundance Of Radio Pharmaceuticals.
3.3.1.5. Technological Advancements.
3.3.1.6. Increasing Need In Emerging Markets.
3.3.1.7. Production Of Radio Pharmaceuticals From Cyclotrons.
3.3.1.8. Efficient Diagnosis And Treatments.
3.3.1.9. Emerging Radioisotopes.
3.3.1.10. Increasing Therapeutic Application Areas.
3.3.1.11. Replacement Of Old/Traditional Equipment.
3.3.2. Restraints and Threats.
3.3.2.1. Regulatory Issues.
3.3.2.2. High Cost And Supply Shortage Of Isotopes.
3.3.2.3. Reduced Half Life Of Radio Pharmaceuticals.
3.3.2.4. Threat From Traditional /Alternative Diagnostic Procedures.
3.3.2.5. Huge Capital Investment.
3.3.2.6. Shortage Of Qualified Technicians.
3.3.2.7. Radio Toxicity.
3.4. Problem Areas.
3.4.1. Closure Of Reactors.
3.5. Winning Imperatives.
3.5.1. Availability Of Technetium.
3.6. Regulatory Guidelines.
3.6.1. United States.
3.6.2. Europe.
3.6.3. Japan.
3.6.4. China.
3.6.5. South Korea.
3.7. Reimbursement Scenario and Challenges.
3.8. Porter's Five Force Analysis.
3.8.1. Threat Of New Entrants.
3.8.2. Threat Of Substitutes.
3.8.3. Bargaining Power Of Suppliers.
3.8.4. Bargaining Power Of Buyers.
3.8.5. Competitive Rivalry.
3.9. Supply Chain Analysis.
3.9.1. Reactors.
3.9.2. Processing Facility.
3.9.3. Generators Manufacturing Units.
3.9.4. Hospitals And Central Radio Pharmacies.
3.10. Market Share Analysis, By Major Players.
3.10.1. Nuclear Medicine Market.
3.10.2. Stable Isotopes Market.

4. Global Nuclear Medicine Market By End-Users.
4.1. Introduction.
4.2. Medicine.
4.2.1. Hospitals.
4.2.2. Diagnostic Centers.
4.3. Academic Research Laboratories.
4.4. Industries.

5. Radiopharmaceuticals By Type.
5.1. Introduction.
5.2. Diagnostics.
5.2.1. Radiopharmaceuticals For Diagnosis, By Isotopes.
5.2.1.1. Spect, By Isotopes.
5.2.1.1.1. Technetium (Tc-99M).
5.2.1.1.2. Thallium (Tl-201).
5.2.1.1.3. Gallium (Ga - 67).
5.2.1.1.4. Iodine (I-123).
5.2.1.1.5. Samarium (Sm-153).
5.2.1.1.6. Yttrium (Y-90).
5.2.1.1.7. Rhenium (Re -186).
5.2.1.1.8. Others.
5.2.1.2. Pet, By Isotopes.
5.2.1.2.1. Fluorodeoxyglucose (Fdg).
5.2.1.2.2. Gallium (Ga-68).
5.2.1.2.3. Rubidium (Rb-82).
5.2.1.2.4. Others.
5.2.2. Radiopharmaceuticals For Diagnosis, By Application.
5.2.2.1. Spect By Application.
5.2.2.1.1. Cardiology.
5.2.2.1.2. Gastro Intestinal.
5.2.2.1.3. Oncology.
5.2.2.1.4. Nephrology.
5.2.2.1.5. Neurology.
5.2.2.1.6. Inflammation.
5.2.2.1.7. Thyroid Glands.
5.2.2.1.8. Lymphology.
5.2.2.1.9. Others.
5.2.2.2. Pet By Application.
5.2.2.2.1. Oncology.
5.2.2.2.2. Neurology.
5.2.2.2.3. Cardiology.
5.2.2.2.4. Inflammation.
5.2.2.2.5. Others.
5.3. Therapeutics.
5.3.1. Radiopharmaceuticals For Therapeutics, By Isotopes.
5.3.1.1. Beta Radiation Therapy, By Isotopes.
5.3.1.1.1. Yttrium (Y-90).
5.3.1.1.2. Iodine (I-131).
5.3.1.1.3. Lutetium (Lu-177).
5.3.1.1.4. Samarium (Sm-153).
5.3.1.1.5. Rhenium (Re-186).
5.3.1.1.6. Strontium (Sr-89).
5.3.1.1.7. Erbium (Er-169).
5.3.1.1.8. Others.
5.3.1.2. Alpha Radiation Therapy, By Isotopes.
5.3.1.2.1. Actinium (Ac-225).
5.3.1.2.2. Astatine (At-211).
5.3.1.2.3. Lead (Pb-212)/Bismuth (Bi-212).
5.3.1.2.4. Radium-224.
5.3.1.2.5. Radium-223.
5.3.1.2.6. Thorium-227 (Th-227).
5.3.1.2.7. Others.
5.3.1.3. Brachytherapy, By Isotopes.
5.3.1.3.1. Iodine (I-125).
5.3.1.3.2. Cesium (Cs-131).
5.3.1.3.3. Iridium (Ir-192).
5.3.1.3.4. Palladium (Pd-103).
5.3.1.3.5. Others.
5.3.2. Therapeutics Radiopharmaceuticals, By Application.
5.3.2.1. Oncology.
5.3.2.2. Nephrology.
5.3.2.3. Cardiology.
5.3.2.4. Neurology.
5.3.2.5. Others.

6. Stable Isotopes.
6.1. Introduction.
6.2. Market Analysis.
6.2.1. Factors Influencing Market.
6.2.1.1. Drivers and Opportunities.
6.2.1.1.1. Stable Isotope - Origin And Safety.
6.2.1.1.2. Increasing Medical Applications.
6.2.1.1.3. Enhanced Clinical Pharmacology.
6.2.1.1.4. System Biology And Proteomics Applications.
6.2.1.1.5. Ecological And Environmental Studies.
6.2.1.2. Restraints And Threat.
6.2.1.2.1. High Cost Of Stable Isotopes.
6.2.1.2.2. Stable Isotopes-Side Effects.
6.2.1.2.3. Usage Of Stable Isotopes For Drug Development.
6.3. Stable Isotopes Market, By Isotopes.
6.3.1. Carbon (C-13).
6.3.2. Deuterium (D2).
6.3.3. Oxygen (O-18).
6.3.4. Nitrogen (N-15).
6.3.5. Sulphur (S-32).
6.3.6. Others.
6.4. Stable Isotopes Market, By Application.
6.4.1. Diagnostics And Therapy.
6.4.2. Pharmaceuticals.
6.4.3. Research.
6.4.4. Industrial Sector.
6.5. Stable Isotopes Market, By Geography.
6.5.1. Introduction.
6.5.2. North America.
6.5.3. Europe.
6.5.4. Asia-Pacific.
6.5.5. Rest Of The World.

7. Regional Market Analysis.
7.1. Introduction.
7.2. North America.
7.3. Europe.
7.4. Asia-Pacific.
7.5. Rest Of The World.

8. Company Developments.
8.1. Introduction.
8.2. Agreements, Partnership, Collaboration and Joint Ventures.
8.3. New Product Launches.
8.4. Approvals.
8.5. Merges and Acquisitions.
8.6. Other Developments.

9. Major Player Profiles.
9.1. Cardinal Health Inc..
9.1.1. Overview.
9.1.2. Financials.
9.1.3. Product Portfolio.
9.1.4. Key Developments.
9.1.5. Business Strategy.
9.1.6. Swot Analysis.
9.2. Cambridge Isotope Laboratories Inc..
9.2.1. Overview.
9.2.2. Financials.
9.2.3. Product Portfolio.
9.2.4. Key Developments.
9.2.5. Business Strategy.
9.2.6. Swot Analysis.
9.3. Ge Healthcare.
9.3.1. Overview.
9.3.2. Financials.
9.3.3. Product Portfolio.
9.3.4. Key Developments.
9.3.5. Business Strategy.
9.3.6. Swot Analysis.
9.4. Iba Group.
9.4.1. Overview.
9.4.2. Financials.
9.4.3. Product Portfolio.
9.4.4. Key Developments.
9.4.5. Business Strategy.
9.4.6. Swot Analysis.
9.5. Isotec Inc.
9.5.1. Overview.
9.5.2. Financials.
9.5.3. Product Portfolio.
9.5.4. Key Developments.
9.5.5. Business Strategy.
9.5.6. Swot Analysis.
9.6. Lantheus Medical Imaging Inc..
9.6.1. Overview.
9.6.2. Financials.
9.6.3. Product Portfolio.
9.6.4. Key Developments.
9.6.5. Business Strategy.
9.6.6. Swot Analysis.
9.7. Mallinckrodt Plc.
9.7.1. Overview.
9.7.2. Financials.
9.7.3. Product Portfolio.
9.7.4. Key Developments.
9.7.5. Business Strategy.
9.7.6. Swot Analysis.
9.8. Nordion Inc.
9.8.1. Overview.
9.8.2. Financials.
9.8.3. Product Portfolio.
9.8.4. Key Developments.
9.8.5. Business Strategy.
9.8.6. Swot Analysis.
9.9. Ntp Radioisotopes Soc Ltd.
9.9.1. Overview.
9.9.2. Financials.
9.9.3. Product Portfolio.
9.9.4. Key Developments.
9.9.5. Business Strategy.
9.9.6. Swot Analysis.
9.10. Taiyo Nippon Sanso Corporation.
9.10.1. Overview.
9.10.2. Financials.
9.10.3. Product Portfolio.
9.10.4. Key Developments.
9.10.5. Business Strategy.
9.10.6. Swot Analysis.

List Of Tables:

Table 1. Global Nuclear Medicine Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 2. Global Nuclear Medicine Market Revenue, By Type
(2012-2020) ($Mn).
Table 3. Global Nuclear Medicine Therapeutic Market Revenue, By Type
(2012-2020) ($Mn).
Table 4. Reimbursement Rates For Bone Scans In United States.
Table 5. Technetium (Tc-99M) Reactors.
Table 6. Technetium (Tc-99M) Processors.
Table 7. Global Nuclear Medicine Market Revenue, By End User
(2012-2020) ($Mn).
Table 8. Global Nuclear Medicine Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 9. Global Nuclear Medicine End User Market Revenue, By Medicine
(2012-2020) ($Mn).
Table 10. Global Nuclear Medicine Hospital End User Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 11. Global Nuclear Medicine Diagnostic Centers End User Market Revenue, By Geography, (2012-2020) ($Mn).
Table 12. Global Nuclear Medicine Academic Research Laboratories End User Market Revenue, By Geography, (2012-2020) ($Mn).
Table 13. Global Nuclear Medicine Industries End User Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 14. Global Nuclear Medicine Market Revenue, By Type (2012-2020) ($Mn).
Table 15. Global Nuclear Medicine Market Revenue, By Geography, (2012-2020) ($Mn).
Table 16. Global Nuclear Medicine Diagnostic Market Revenue, By Type,
(2012-2020) ($Mn).
Table 17. Global Nuclear Medicine Diagnostic Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 18. Global Nuclear Medicine Spect Market Revenue, By Isotopes, (2012-2020) ($Mn).
Table 19. Global Nuclear Medicine Spect Isotopes Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 20 Global Spect Technetium (Tc-99M) Market Revenue, By Geography, (2012-2020) ($Mn). . . .
Table 21. Global Spect Thallium (Tl-201) Market Revenue, By Geography, (2012-2020) ($Mn).
Table 22. Global Spect Gallium (Ga-67) Market Revenue, By Geography, (2012-2020) ($Mn).
Table 23. Global Spect Iodine (I-123) Market Revenue, By Geography, (2012-2020) ($Mn).
Table 24. Global Spect Samarium (Sm-153) Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 25. Global Spect Yttrium (Y-90) Market Revenue, By Geography, (2012-2020) ($Mn).
Table 26. Global Spect Rhenium (Re-186) Market Revenue, By Geography, (2012-2020) ($Mn).
Table 27. Global Spect Other Isotopes Market Revenue, By Geography, (2012-2020) ($Mn).
Table 28. Global Nuclear Medicine Pet Market Revenue, By Isotopes, (2012-2020) ($Mn).
Table 29. Global Nuclear Medicine Pet Isotopes Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 30. Global Pet Fluorodeoxyglucose (18F-Fdg) Market Revenue, By Geography,
(2012-2020) $Mn).
Table 31. Global Pet Gallium (Ga-68) Market Revenue, By Geography, (2012-2020) ($Mn).
Table 32. Global Pet Rubidium (Rb-82) Market Revenue, By Geography, (2012-2020) ($Mn).
Table 33. Global Pet Other Isotopes Market Revenue, By Geography, (2012-2020) ($Mn).
Table 34. Global Nuclear Medicine Spect Market Revenue, By Application (2012-2020) ($Mn).
Table 35. Global Spect Cardiology Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 36. Global Spect Gastro Intestinal Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 37. Global Spect Oncology Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 38. Global Spect Nephrology Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 39. Global Spect Neurology Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 40. Global Spect Inflammation Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 41. Global Spect Thyroid Glands Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 42. Global Spect Lymphology Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 43. Global Spect Other Applications Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 44. Global Nuclear Medicine Pet Market Revenue, By Application
(2012-2020) ($Mn).
Table 45. Global Pet Oncology Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 46. Global Pet Neurology Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 47. Global Pet Cardiology Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 48. Global Pet Inflammation Applications Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 49. Global Pet Other Applications Market Revenue, By Geography, (2012-2020) ($Mn).
Table 50. Global Nuclear Medicine Therapeutic Market Revenue, By Type (2012-2020) ($Mn).
Table 51. Global Nuclear Medicine Therapeutic Application Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 52. Global Nuclear Medicine Beta Radiation Therapy Market Revenue, By Isotopes
(2012-2020) ($Mn).
Table 53. Global Nuclear Medicine Beta Radiation Therapy Isotopes Market Revenue,
By Geography, (2012-2020) ($Mn).
Table 54. Global Nuclear Medicine Beta Radiation Yttrium (Y-90) Market Revenue,
By Geography, (2012-2020) ($Mn).
Table 55. Global Nuclear Medicine Beta Radiation Iodine (I-131) Market Revenue,
By Geography, (2012-2020) ($Mn).
Table 56. Global Nuclear Medicine Beta Radiation Lutetium (Lu-177) Market Revenue,
By Geography, (2012-2020) ($Mn).
Table 57. Global Nuclear Medicine Beta Radiation Samarium (Sm-153) Market Revenue, By Geography, (2012-2020) ($Mn).
Table 58. Global Nuclear Medicine Beta Radiation Rhenium (Re-186) Market Revenue,
By Geography, (2012-2020) ($Mn).
Table 59. Global Nuclear Medicine Beta Radiation Strontium (Sr-89) Market Revenue,
By Geography, (2012-2020) ($Mn).
Table 60. Global Nuclear Medicine Beta Radiation Erbium (Er-169) Market Revenue,
By Geography, (2012-2020) ($Mn).
Table 61. Global Nuclear Medicine Beta Radiation Other Isotopes Market Revenue,
By Geography, (2012-2020) ($Mn).
Table 62. Global Nuclear Medicine Brachytherapy Market Revenue, By Isotopes
(2012-2020) ($Mn).
Table 63. Global Nuclear Medicine Brachytherapy Isotopes Market Revenue, By Geography,
(2012-2020) ($Mn).
Table 64. Global Nuclear Medicine Iodine (I-125) Brachytherapy Isotopes Market Revenue, By Geography, (2012-2020) ($Mn).
Table 65. Global Nuclear Medicine Cesium (Cs-131) Brachytherapy Isotopes Market Revenue, By Geography, (2012-2020) ($Mn).
Table 66. Global Nuclear Medicine Iridium (Ir-192) Brachytherapy Isotopes Market Revenue, By Geography, (2012-2020) ($Mn).
Table 67. Global Nuclear Medicine Palladium (Pd-103) Brachytherapy Isotopes Market Revenue,
By Geography, (2012-2020).
Table 68. Global Nuclear Medicine Other Brachytherapy Isotopes Market Revenue,
By Geography, (2012-2020) ($Mn).
Table 69. Global Nuclear Medicine Therapeutic Market Revenue, By Application
(2012-2020) ($Mn).
Table 70. Global Nuclear Medicine Oncology Therapeutic Application Market Revenue,
By Geography, (2012-2020) ($Mn).
Table 71. Global Nuclear Medicine Nephrology Therapeutic Application Market Revenue, By Geography, (2012-2020) ($Mn).
Table 72. Global Nuclear Medicine Cardiology Therapeutic Application Market Revenue, By Geography, (2012-2020) ($Mn).
Table 73. Global Nuclear Medicine Neurology Therapeutic Application Market Revenue, By Geography, (2012-2020) ($Mn).
Table 74. Global Nuclear Medicine Other Therapeutic Application Market Revenue,
By Geography, (2012-2020) ($Mn).
Table 75. Global Stable Isotopes Market Revenue, By Isotopes (2012-2020) ($Mn).
Table 76. Global Stable Isotopes Market Revenue, By Geography (2012-2020) ($Mn).
Table 77. Global Carbon (C-13) Stable Isotopes Market Revenue, By Geography
(2012-2020) ($Mn).
Table 78. Global Deuterium (D2) Stable Isotopes Market Revenue, By Geography
(2012-2020) ($Mn).
Table 79. Global Oxygen (O-18) Stable Isotopes Market Revenue, By Geography
(2012-2020) ($Mn).
Table 80. Global Nitrogen (N-15) Stable Isotopes Market Revenue, By Geography (2012-2020) ($Mn).
Table 81. Global Sulphur (S-32) Stable Isotopes Market Revenue, By Geography
(2012-2020) ($Mn).
Table 82. Global Other Stable Isotopes Market Revenue, By Geography (2012-2020) ($Mn).
Table 83. Global Stable Isotopes Market Revenue, By Application (2012-2020) ($Mn).
Table 84. Global Stable Isotopes Diagnostics and Therapy Applications Market Revenue,
By Geography (2012-2020) ($Mn).
Table 85. Global Stable Isotopes Pharmaceutical Applications Market Revenue, By Geography
(2012-2020) ($Mn).
Table 86. Global Stable Isotopes Research Applications Market Revenue, By Geography
(2012-2020) ($Mn).
Table 87. Global Stable Isotopes Industrial Sector Applications Market Revenue, By Geography (2012-2020) ($Mn).
Table 88. North American Stable Isotopes Market Revenue, By Isotopes (2012-2020) ($Mn).
Table 89. North American Stable Isotopes Market Revenue, By Application
(2012-2020) ($Mn).
Table 90. European Stable Isotopes Market Revenue, By Isotopes (2012-2020) ($Mn).
Table 91. European Stable Isotopes Market Revenue, By Application (2012-2020) ($Mn).
Table 92. Asia-Pacific Stable Isotopes Market Revenue, By Isotopes (2012-2020) ($Mn).
Table 93. Asia-Pacific Stable Isotopes Market Revenue, By Application (2012-2020) ($Mn).
Table 94. Rest Of The World Stable Isotopes Market Revenue, By Isotopes
(2012-2020) ($Mn).
Table 95. Rest Of The World Stable Isotopes Market Revenue, By Application
(2012-2020) ($Mn).
Table 96. North American Nuclear Medicine Market Revenue, By End User (2012-2020) ($Mn).
Table 97. North American Nuclear Medicine End User Market Revenue, By Medicine
(2012-2020) ($Mn).
Table 98. North American Nuclear Medicine Market Revenue, By Type (2012-2020) ($Mn).
Table 99. North American Nuclear Medicine Diagnostic Market Revenue, By Type,
(2012-2020) ($Mn).
Table 100 North American Nuclear Medicine Spect Market Revenue, By Isotopes,
(2012-2020) ($Mn).
Table 101 North American Nuclear Medicine Pet Market Revenue, By Isotopes, (2012-2020) ($Mn). . . .
Table 102 North American Nuclear Medicine Spect Market Revenue, By Application (2012-2020) ($Mn).
Table 103 North American Nuclear Medicine Pet Market Revenue, By Application
(2012-2020) ($Mn).
Table 104 North American Nuclear Medicine Therapeutic Market Revenue, By Type
(2012-2020) ($Mn).
Table 105. North American Nuclear Medicine Beta Radiation Therapy Market Revenue,
By Isotopes (2012-2020) ($Mn).
Table 106. North American Nuclear Medicine Brachytherapy Market Revenue,
By Isotopes (2012-2020) ($Mn).
Table 107. North American Nuclear Medicine Therapeutic Market Revenue, By Application
(2012-2020) ($Mn).
Table 108. European Nuclear Medicine Market Revenue, By End User
(2012-2020) ($Mn).
Table 109. European Nuclear Medicine End User Market Revenue, By Medicine
(2012-2020) ($Mn).
Table 110. European Nuclear Medicine Market Revenue, By Type (2012-2020) ($Mn).
Table 111. European Nuclear Medicine Diagnostic Market Revenue, By Type,
(2012-2020) ($Mn).
Table 112. European Nuclear Medicine Spect Market Revenue, By Isotopes,
(2012-2020) ($Mn).
Table 113. European Nuclear Medicine Pet Market Revenue, By Isotopes,
(2012-2020) ($Mn).
Table 114. European Nuclear Medicine Spect Market Revenue, By Application
(2012-2020) ($Mn).
Table 115. European Nuclear Medicine Pet Market Revenue, By Application
(2012-2020) ($Mn).
Table 116. European Nuclear Medicine Therapeutic Market Revenue, By Type
(2012-2020) ($Mn).
Table 117. European Nuclear Medicine Beta Radiation Therapy Market Revenue, By Isotopes (2012-2020) ($Mn).
Table 118. European Nuclear Medicine Brachytherapy Market Revenue, By Isotopes
(2012-2020) ($Mn).
Table 119. European Nuclear Medicine Therapeutic Market Revenue, By Application
(2012-2020) ($Mn).
Table 120. Asia-Pacific Nuclear Medicine Market Revenue, By End User (2012-2020) ($Mn).
Table 121. Asia-Pacific Nuclear Medicine End User Market Revenue, By Medicine
(2012-2020) ($Mn).
Table 122. Asia-Pacific Nuclear Medicine Market Revenue, By Type (2012-2020) ($Mn).
Table 123. Asia-Pacific Nuclear Medicine Diagnostic Market Revenue, By Type,
(2012-2020) ($Mn).
Table 124. Asia-Pacific Nuclear Medicine Spect Market Revenue, By Isotopes,
(2012-2020) ($Mn).
Table 125. Asia-Pacific Nuclear Medicine Pet Market Revenue, By Isotopes,
(2012-2020) ($Mn).
Table 126. Asia-Pacific Nuclear Medicine Spect Market Revenue, By Application
(2012-2020) ($Mn).
Table 127. Asia-Pacific Nuclear Medicine Pet Market Revenue, By Application
(2012-2020) ($Mn).
Table 128. Asia-Pacific Nuclear Medicine Therapeutic Market Revenue, By Type
(2012-2020) ($Mn).
Table 129. Asia-Pacific Nuclear Medicine Beta Radiation Therapy Market Revenue,
By Isotopes (2012-2020) ($Mn).
Table 130. Asia-Pacific Nuclear Medicine Brachytherapy Market Revenue,
By Isotopes (2012-2020) ($Mn).
Table 131. Asia-Pacific Nuclear Medicine Therapeutic Market Revenue, By Application
(2012-2020) ($Mn).
Table 132. Row Nuclear Medicine Market Revenue, By End User (2012-2020) ($Mn).
Table 133. Row Nuclear Medicine End User Market Revenue, By Medicine
(2012-2020) ($Mn).
Table 134. Row Nuclear Medicine Market Revenue, By Type (2012-2020) ($Mn).
Table 135. Row Nuclear Medicine Diagnostic Market Revenue, By Type, (2012-2020) ($Mn).
Table 136. Row Nuclear Medicine Spect Market Revenue, By Isotopes, (2012-2020) ($Mn).
Table 137. Row Nuclear Medicine Pet Market Revenue, By Isotopes, (2012-2020) ($Mn).
Table 138. Row Nuclear Medicine Spect Market Revenue, By Application (2012-2020) ($Mn).
Table 139. Row Nuclear Medicine Pet Market Revenue, By Application (2012-2020) ($Mn).
Table 140. Row Nuclear Medicine Therapeutic Market Revenue, By Type (2012-2020) ($Mn).
Table 141. Row Nuclear Medicine Beta Radiation Therapy Market Revenue, By Isotopes
(2012-2020) ($Mn).
Table 142. Row Nuclear Medicine Brachytherapy Market Revenue, By Isotopes
(2012-2020) ($Mn).
Table 143. Row Nuclear Medicine Therapeutic Market Revenue, By Application
(2012-2020) ($Mn).
Table 144. Agreements, Partnership, Collaboration and Joint Ventures (2011-2014).
Table 145. New Product Launches (2011-2014).
Table 146. Approvals (2011-2014).
Table 147. Merges and Acquisitions (2011-2014).
Table 148. Other Developments (2011-2014).
Table 149. Cardinal Health, Inc.: Total Revenue And Operating Expenses (2011-2013) ($Mn).
Table 150. Cardinal Health, Inc.: Total Revenue, By Segments (2011-2013) ($Mn).
Table 151. Cardinal Health, Inc.: Total Revenue, By Geography (2011-2013) ($Mn).
Table 152. General Electric Company: Total Revenue And RandD Expenses (2011 - 2013) ($Bn).
Table 153. General Electric Company: Total Revenue, By Segments (2011-2013) ($Bn).
Table 154. General Electric Company: Total Revenue, By Geography (2011 - 2013) ($Bn).
Table 155. Iba Group: Total Revenue And RandD Expenses (2011 - 2013) ($Mn).
Table 156. Iba Group: Total Revenue, By Segments (2011 - 2013) ($Mn).
Table 157. Isotec, Inc: Total Revenue And RandD Expenses (2011-2013) ($Mn).
Table 158. Isotec, Inc: Total Revenue, By Segments (2011-2013) ($Mn).
Table 159. Isotec, Inc: Total Revenue, By Geography (2011-2013) ($Mn).
Table 160. Lantheus Medical Imaging Inc.: Total Revenue And RandD Expenses,
2011-2013 ($Mn).
Table 161. Lantheus Medical Imaging Inc.: Total Revenue, By Products
(2011-2013) ($Mn).
Table 162. Lantheus Medical Imaging Inc.: Total Revenue, By Geography
(2011-2013) ($Mn).
Table 163. Mallinckrodt Plc: Total Sales And RandD Expenses (2011-2013) ($Bn).
Table 164. Mallinckrodt Plc: Total Revenue, By Segments (2011- 2013) ($Bn).
Table 165. Mallinckrodt Plc: Total Revenue, By Geography (2011- 2013) ($Bn).
Table 166. Nordion Inc: Total Revenue And RandD Expenses (2011-2013) ($Mn).
Table 167. Nordion Inc: Total Revenue, By Segments (2011-2013) ($Mn).
Table 168. Nordion Inc: Medical Isotope Revenue, By Segments (2011-2013) ($Mn).
Table 169. Nordion Inc: Total Revenue, By Geography (2011-2013) ($Mn).
Table 170. Ntp Radioisotopes Soc Ltd: Total Sales And RandD Expenses (2011-2013) ($Mn).
Table 171. Ntp Radioisotopes Soc Ltd: Total Revenue, By Segments (2011-2013) ($Mn).
Table 172. Taiyo Nippon Sanso Corporation: Total Revenue And RandD Expenses
(2011-2013) ($Mn).
Table 173. Taiyo Nippon Sanso Corporation: Total Revenue, By Segments
(2011-2013) ($Mn).
Table 174. Taiyo Nippon Sanso Corporation: Total Revenue, By Geography
(2011-2013) ($Mn).

List Of Figures:

Figure 1. Global Nuclear Medicine Market Share, By Geography (2013).
Figure 2. Nuclear Medicine/Radiopharmaceuticals Market: Research Approach.
Figure 3. Nuclear Medicine Market: Top-Down And Bottom-Up Approach.
Figure 4. Nuclear Medicine Market: Forecasting Model.
Figure 5. Nuclear Medicine Market: Market Breakdown and Data Triangulation.
Figure 6. Nuclear Medicine Market: Market Segmentation.
Figure 7. Nuclear Medicine Market: Market Dynamics.
Figure 8. Nuclear Medicine Market: Porter'S Analysis.
Figure 9. Technetium (Tc-99M) Reactors.
Figure 10. Technetium (Tc-99M) Processors.
Figure 11. Technetium -99: Supply Chain Analysis.
Figure 12. Nuclear Medicine Market: Major Player Analysis (2013).
Figure 13. Stable Isotopes Market: Major Player Analysis (2013).
Figure 14. Stable Isotopes Market: Market Dynamics.
Figure 15. Key Growth Strategies, (2011-2014).
Figure 16. Swot: Cardinal Health, Inc..
Figure 17. Swot: Cambridge Isotope Laboratories Inc..
Figure 18. Swot: Ge Healthcare.
Figure 19. Swot: Iba Group.
Figure 20. Swot: Isotec Inc.
Figure 21. Swot: Lantheus Medical Imaging Inc..
Figure 22. Swot: Mallinckrodt Plc.
Figure 23. Swot: Nordion Inc.
Figure 24. Swot: Ntp Radioisotopes Soc Ltd.
Figure 25. Swot: Taiyo Nippon Sanso Corporation.

Companies Mentioned

CIL
Cardinal Health, Inc.
GE Healthcare
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Mallinckrodt Plc
NTP Radioisotopes
Nordion Inc
Taiyo Nippon Sanso Corporation

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...

Global Nuclear Medicine Market

Global Nuclear Medicine Market

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global nuclear medicines market is expected to reach USD 17,600 million by the end of 2020, growing at a CAGR of around 12.29% from 2015 to 2020. Nuclear medicine utilizes the radioisotope for application ...

Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2016 Market Research Report

Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global European ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.